Your browser doesn't support javascript.
loading
Administration of Tranexamic Acid After Burr Hole Craniotomy Reduced Postoperative Recurrence of Chronic Subdural Hematoma in a Japanese Regional Population.
Miyakoshi, Akinori; Nakatani, Eiji; Kaneda, Hideaki; Hawke, Philip; Sasaki, Hatoko; Urano, Tetsumei; Miyachi, Yoshiki.
Afiliación
  • Miyakoshi A; Shizuoka Graduate University of Public Health, Shizuoka , Japan.
  • Nakatani E; Department of Neurosurgery, Shizuoka General Hospital, Shizuoka , Japan.
  • Kaneda H; Shizuoka Graduate University of Public Health, Shizuoka , Japan.
  • Hawke P; Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Hyogo , Japan.
  • Sasaki H; School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka , Japan.
  • Urano T; Shizuoka Graduate University of Public Health, Shizuoka , Japan.
  • Miyachi Y; Shizuoka Graduate University of Public Health, Shizuoka , Japan.
Neurosurgery ; 93(5): 1160-1167, 2023 Nov 01.
Article en En | MEDLINE | ID: mdl-37288980
BACKGROUND: Although tranexamic acid (TXA) has occasionally been used to prevent postoperative recurrence of chronic subdural hematoma (CSDH) after burr hole craniotomy (BC), robust evidence of its efficacy has been lacking. OBJECTIVE: To assess the efficacy and safety of postoperative oral administration of TXA after BC for CSDH among the elderly. METHODS: This retrospective, propensity score-matched cohort study was carried out with a large Japanese local population-based longitudinal cohort in the Shizuoka Kokuho Database between April 2012 and September 2020. Patients included were age 60 years or older and had undergone BC for CSDH but were not undergoing dialysis. Covariates were collected from records of the preceding 12 months from the month of first BC, and patients were followed up for 6 months after surgery. The primary outcome was repeat surgery, and the secondary outcome was death or the onset of thrombosis. Data on postoperative TXA administration were collected and compared with controls using propensity score matching. RESULTS: Of the 8544 patients who underwent BC for CSDH, 6647 were included, with 473 placed in the TXA group and 6174 placed in the control group. After 1:1 matching, repeated BC was found to have been performed in 30 of 465 patients (6.5%) in the TXA group and in 78 of 465 patients (16.8%) in the control group (relative risk, 0.38; 95% CI, 0.26-0.56). No significant difference was observed for death or the onset of thrombosis. CONCLUSION: Oral administration of TXA reduced the occurrence of repeat surgery after BC for CSDH.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trombosis / Ácido Tranexámico / Hematoma Subdural Crónico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Neurosurgery Año: 2023 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trombosis / Ácido Tranexámico / Hematoma Subdural Crónico Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged País/Región como asunto: Asia Idioma: En Revista: Neurosurgery Año: 2023 Tipo del documento: Article País de afiliación: Japón